IFM Investors Pty Ltd Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

IFM Investors Pty Ltd grew its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 11.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,372 shares of the life sciences company's stock after purchasing an additional 3,309 shares during the quarter. IFM Investors Pty Ltd's holdings in Illumina were worth $2,568,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Freedom Investment Management Inc. grew its holdings in Illumina by 3.7% during the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock valued at $382,000 after buying an additional 101 shares in the last quarter. Personal CFO Solutions LLC raised its position in Illumina by 9.2% in the 4th quarter. Personal CFO Solutions LLC now owns 1,789 shares of the life sciences company's stock worth $239,000 after purchasing an additional 150 shares during the period. GC Wealth Management RIA LLC lifted its stake in Illumina by 9.5% in the fourth quarter. GC Wealth Management RIA LLC now owns 1,783 shares of the life sciences company's stock worth $238,000 after purchasing an additional 154 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Illumina by 16.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,108 shares of the life sciences company's stock valued at $148,000 after buying an additional 156 shares during the period. Finally, Signaturefd LLC grew its position in Illumina by 10.4% in the 4th quarter. Signaturefd LLC now owns 1,880 shares of the life sciences company's stock valued at $251,000 after acquiring an additional 177 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Price Performance

Illumina stock traded down $1.83 during trading on Wednesday, reaching $97.44. The company had a trading volume of 3,002,706 shares, compared to its average volume of 2,154,975. The firm has a market capitalization of $15.42 billion, a PE ratio of -16.05, a price-to-earnings-growth ratio of 1.95 and a beta of 1.36. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The firm's 50-day simple moving average is $85.88 and its 200 day simple moving average is $96.96. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter last year, the business posted $0.98 earnings per share. The business's quarterly revenue was down 1.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, CFO Ankur Dhingra bought 6,100 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the purchase, the chief financial officer owned 24,906 shares in the company, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ILMN shares. Evercore ISI upped their price target on shares of Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a report on Tuesday. Royal Bank Of Canada dropped their target price on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. JPMorgan Chase & Co. reduced their target price on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group boosted their price target on Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a report on Wednesday, June 11th. Finally, Morgan Stanley reduced their price objective on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of "Hold" and a consensus target price of $127.16.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.